Literature DB >> 34929892

Comorbidities and mortality in COVID-19 patients.

Irawaty Djaharuddin1, Sitti Munawwarah2, Asvin Nurulita3, Muh Ilyas2, Nur Ahmad Tabri2, Nurjannah Lihawa2.   

Abstract

BACKGROUND: The high mortality rate in Coronavirus Disease (COVID-19) patients is associated with their comorbid conditions. Therefore, it is important to identify risk factors associated with poor outcomes among COVID-19 patients. The aims of this study were to find out the comorbidities in case of death due to COVID-19.
METHODS: The design of this study was a retrospective descriptive method with a confirmed COVID-19 patient on hospitalized at Dr. Wahidin Sudirohusodo Hospital from March to September 2020. Ethics Council recommendation number: 357/UN4.6.4.5.31/PP36/2020.
RESULTS: A total of 454 patients were included of this study. 78 (17.18%) patients death due to COVID-19, consisting of 52 (66.67%) male and 26 (33.33%) female. Range of ages between 18 and 85 years. The highest mortality rate occurred in the age group ≥60 years (35; 51.47%), followed by the age group of 45-59 years (33; 48.53%), and the age group of <45 years (10; 12%). The prevalent comorbidity was hypertension (42.31%), cardiovascular disease (30.77%), diabetes (28.21%), chronic kidney disease (23.08%), malignancy (15.38%), obesity (15.38%), chronic liver disease (7.69%), chronic respiratory disease (6.41%), immune related disease (3.85%), and non-traumatic cerebral infarction (3.85%). 41 (52.56%) patients reported having two or more comorbidities, and 37 (47.44%) only has one comorbidity. Elevated neutrophil-to-lymphocyte ratio (NLR) ≥3.13 was seen in the majority of patients (68; 87.18%). The mean value of NLR was 20.94.
CONCLUSIONS: Hypertension, cardiovascular disease, and diabetes were the most common comorbidity in patients death due to COVID-19. More than half of the patients had two or more comorbidities.
Copyright © 2021 SESPAS. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  COVID-19; Comorbidities; Mortality

Mesh:

Year:  2021        PMID: 34929892      PMCID: PMC8677356          DOI: 10.1016/j.gaceta.2021.10.085

Source DB:  PubMed          Journal:  Gac Sanit        ISSN: 0213-9111            Impact factor:   2.139


Introduction

On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. As of 09 September, the Government of Indonesia announced 203.342 confirmed cases of COVID-19 and 8.336 deaths. Data from China have indicated that older adults, particularly those with serious underlying health conditions, are at higher risk for severe COVID-19-associated illness and death than are younger persons. Although the majority of reported COVID-19 cases in China were mild (81%), approximately 80% of deaths occurred among adults aged ≥60 years. This first preliminary description of outcomes among patients with COVID-19 in the United States indicates that fatality was highest in persons aged ≥85, ranging from 10% to 27%, followed by 3% to 11% among persons aged 65–84 years. Over 180 countries have been affected by COVID-19, resulting in mass death worldwide. As cases evolve globally, it has been noted that persons with underlying chronic illnesses are more likely to contract the virus and become severely ill. Due to SARS CoV-2 being a relatively new virus, the data available is limited. However, patients with comorbidities have more deteriorating outcomes compared with patients without. COVID-19 patients with history of hypertension, obesity, chronic lung disease, diabetes, and cardiovascular disease have the worst prognosis and most often end up with deteriorating outcomes such as ARDS and pneumonia. Also, elderly patients in long-term care facilities, chronic kidney disease patients, and cancer patients are not only at risk for contracting the virus, but there is a significantly increased risk of death among these groups of patients. The high mortality rate in COVID-19 patients is associated with their comorbid conditions. Therefore, it is important to identify risk factors associated with poor outcomes among COVID-19 patients. The aims of this study were to find out the comorbidities in case of death due to COVID-19.

Methods

The design of this study was a retrospective descriptive method with the sampling technique in this study was carried out purposively on COVID-19 patients who entered and were treated at the WS Hospital from the period March to September 2020, total of 454 patients were included of this study. Ethical clearance from ethics committee Hasanuddin University, with number 357/UN4.6.4.5.31/PP36/2020.

Result

A total of 454 patients were included of this study, consisting of 225 (49.56%) male and 229 (50.44%) females. Among 78 (17.18%) patients had been reported death due to COVID-19 (Fig. 1 ).
Fig. 1

Outcome of confirmed COVID-19 patients.

Outcome of confirmed COVID-19 patients. Two-thirds of them are male. Range of ages between 18 and 85 years with average 57 years. The highest mortality rate occurred in the age group ≥60 years (35; 51.47%), followed by the age group of 45–59 years (33; 48.53%), and the age group of <45 years (10; 12%). The most comorbidity was hypertension (42.31%), cardiovascular disease (30.77%), and diabetes (28.21%) (Fig. 2 ).
Fig. 2

Comorbidities of patients death due to COVID-19.

Comorbidities of patients death due to COVID-19. Elevated NLR ≥3.13 was seen in the majority of patients (68; 87.18%) with the mean value of NLR was 20.94. Characteristic of patient is available in Table 1 .
Table 1

Characteristics of patients death due to COVID-19.

CharacteristicsTotal (n = 78)Percentage (%)
Sex
 Male5266.67
 Female2633.33
Age
 <451012.82
 45–593348.53
 ≥603551.47
Comorbidity
 Hypertension3342.31
 Cardiovascular disease2430.77
 Diabetes2228.21
 Chronic kidney disease1823.08
 Malignancy1215.38
 Obesity1215.38
 Chronic liver disease67.69
 Chronic respiratory disease56.41
 Immune related disease33.85
 Infark cerebri non traumatik33.85
Number of comorbidities
 1 comorbidity3747.44
 ≥2 comorbidities4152.56
NLR
 <3.131012.82
 ≥3.136887.18
Characteristics of patients death due to COVID-19.

Discussion

In this study, the mortality rate was quite large, 17.18%. The high mortality rate indicates the severity of the disease and the presence of comorbid conditions. A high mortality rate was also reported in US. The study includes the first large case series of sequentially hospitalized patients with confirmed COVID-19 in the US. There were 21% of patients died, among patients who were discharged or died (n: 2634). In a retrospective cohort study from China, hospitalized patients were predominantly men with a median age of 56 years; 26% required intensive care unit (ICU) care, and there was a 28% mortality rate. The men's mortality rate was higher than for women (66.67% vs. 33.33%). The systematic literature review and meta-analysis by Ortolan et al., data pooling resulted in a significant association between male sex and mortality (OR = 1.81; 95% CI 1.25–2.62). Emerging evidence has suggested that ACE2 is a co-receptor for SARS-CoV-2 viral entry into the human cell that plays a significant role in the pathogenesis of this virus. A study has suggested that ACE2 expression was higher in Asian males. Other explanations to why men were associated with severe outcomes compared with women in response to COVID-19 infection may involve differences in immunologic reaction and the lack of protective effect of estrogen signaling seen in females. We found the highest mortality rate occurred in the age group ≥60 years (35; 51.47%). The condition of geriatric patients also increases the likelihood of a cytokine storm when exposed to COVID-19 because geriatrics have an immunosenescence condition (decreased immunity in old age). The presence of immunosenesscences in the elderly causes susceptibility to respiratory tract infections. This can occur due to reduced mucosal barrier, mucociliary clearance, immune response and the presence of respiratory inflammation against pathogenic microorganisms. Mucociliary clearance is reduced due to a decrease in the number and activity of cilia in the upper respiratory tract. It can also reduce the ability of the respiratory system to neutralize viral infections. Immune system dysfunction such as in the case of immunosenessence can cause susceptibility and severity of clinical manifestations of COVID-19 in the elderly population. This is caused by uncontrolled infection due to a weak immune system resulting in multi-organ failure, especially in organs or systems that have a lot of ACE2 such as the respiratory, cardiovascular, hepatic, and renal systems. Karyono DR and Wicaksana AL reported on their research that the mortality rate was higher among elderly patients with COVID-19 and COVID-19 patients with hypertension, diabetes, and other cardiovascular diseases. Leading comorbidities among COVID-19 deaths in NY, USA were hypertension (55.4%), diabetes (37.3%), hyperlipidemia (18.5%). A total of 5700 patients were included, the most common comorbidities were hypertension (3026, 56.6%), obesity (1737, 41.7%), and diabetes (1808, 33.8%). In this study, the most comorbidities were hypertension (42.31%), cardiovascular disease (30.77%) and diabetes (28.21%). More than half of patients (52.56%) death due to COVID-19 had ≥2 comorbids and the rest had only one comorbid. Guan WJ et al. analyzed data from 1590 laboratory confirmed hospitalized patients from 575 hospitals in 31 provinces China. This study analyzed the composite end-points, which consisted of admission to an Intensive Care unit, invasive ventilation or death. Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. A greater number of comorbidities also correlated with poorer clinical outcomes. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities. The data of 61 patients with confirmed COVID-19 were analyzed, the baseline characteristics of patients in the mild and severe groups were described and compared, and the dynamic changes of laboratory indexes and imaging were demonstrated. The independent risk factors affecting incidence of severe illness were screened. The results showed that NLR was the most significant factor affecting the severe illness incidence, and it had significant predictive value. Furthermore, according to the NLR and age stratification, the incidence of severe ill ones with NLR ≥3.13 and aged ≥50 years old was 50%, and 9.1% in age ≥50 and NLR < 3.13 patients.

Conclusion

The mortality rate for hospitalized COVID-19 patients is 17.18%. Hipertension, cardiovascular disease, and diabetes were the most common comorbidity in patients death due to COVID-19. More than half of the patients had two or more comorbidities.

Conflicts of interest

The authors declare no conflict of interest.
  12 in total

1.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.

Authors:  Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos
Journal:  JAMA       Date:  2020-05-26       Impact factor: 56.272

2.  [Consideration on the strategies during epidemic stage changing from emergency response to continuous prevention and control].

Authors: 
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2020-03-10

3.  Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection.

Authors:  Rudragouda Channappanavar; Craig Fett; Matthias Mack; Patrick P Ten Eyck; David K Meyerholz; Stanley Perlman
Journal:  J Immunol       Date:  2017-04-03       Impact factor: 5.422

Review 4.  Comorbidity and its Impact on Patients with COVID-19.

Authors:  Adekunle Sanyaolu; Chuku Okorie; Aleksandra Marinkovic; Risha Patidar; Kokab Younis; Priyank Desai; Zaheeda Hosein; Inderbir Padda; Jasmine Mangat; Mohsin Altaf
Journal:  SN Compr Clin Med       Date:  2020-06-25

5.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

6.  Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage.

Authors:  Jingyuan Liu; Yao Liu; Pan Xiang; Lin Pu; Haofeng Xiong; Chuansheng Li; Ming Zhang; Jianbo Tan; Yanli Xu; Rui Song; Meihua Song; Lin Wang; Wei Zhang; Bing Han; Li Yang; Xiaojing Wang; Guiqin Zhou; Ting Zhang; Ben Li; Yanbin Wang; Zhihai Chen; Xianbo Wang
Journal:  J Transl Med       Date:  2020-05-20       Impact factor: 5.531

7.  Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2.

Authors:  Yu Zhao; Zixian Zhao; Yujia Wang; Yueqing Zhou; Yu Ma; Wei Zuo
Journal:  Am J Respir Crit Care Med       Date:  2020-09-01       Impact factor: 21.405

8.  Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis.

Authors:  Augusta Ortolan; Mariagrazia Lorenzin; Mara Felicetti; Andrea Doria; Roberta Ramonda
Journal:  Int J Infect Dis       Date:  2020-08-12       Impact factor: 3.623

9.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

10.  Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-03-27       Impact factor: 17.586

View more
  9 in total

Review 1.  Utility of NO and H2S donating platforms in managing COVID-19: Rationale and promise.

Authors:  Palak P Oza; Khosrow Kashfi
Journal:  Nitric Oxide       Date:  2022-08-24       Impact factor: 4.898

2.  COVID-19 in Africa: An Explorative Cross-Sectional Analysis of Twenty-One African Countries From January to June 2020.

Authors:  Toluwalase Awoyemi; Ayokunle Adenipekun; Roseline Chima-Kalu; Olubukola Adedayo; Joshua Obarombi; Oluwamayowa Bello; Oluwaseun Bello; Danladi Adamu
Journal:  Cureus       Date:  2022-05-06

Review 3.  How can Biology of Aging Explain the Severity of COVID-19 in Older Adults.

Authors:  Antonella Gallo; Erika Pero; Simona Pellegrino; Noemi Macerola; Celeste Ambra Murace; Francesca Ibba; Maria Chiara Agnitelli; Francesco Landi; Massimo Montalto
Journal:  Clin Geriatr Med       Date:  2022-04-22       Impact factor: 3.529

4.  Comparative analysis of neutrophil to lymphocyte ratio and derived neutrophil to lymphocyte ratio with respect to outcomes of in-hospital coronavirus disease 2019 patients: A retrospective study.

Authors:  Muhammad Sohaib Asghar; Mohammed Akram; Farah Yasmin; Hala Najeeb; Unaiza Naeem; Mrunanjali Gaddam; Muhammad Saad Jafri; Muhammad Junaid Tahir; Iqra Yasin; Hamid Mahmood; Qasim Mehmood; Roy Rillera Marzo
Journal:  Front Med (Lausanne)       Date:  2022-07-22

5.  Clinical Characteristics, Outcomes and Prognostic Factors for Critical Illness in Hospitalized COVID-19 Patients in Saudi Arabia: A Retrospective Cohort Study.

Authors:  Asmaa M El-Kady; Fahad M Aldakheel; Khaled S Allemailem; Ahmad Almatroudi; Reem Dbas Alharbi; Hamad Al Hamed; Muslimah Alsulami; Wafa A Alshehri; Saeed El-Ashram; Eugene Kreys; Khalil Mohamed; Wafa Abdullah I Al-Megrin; Hatem A Elshabrawy
Journal:  Int J Gen Med       Date:  2022-08-31

6.  Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19).

Authors:  Sami Ullah; Radhya Abid; Sana Haider; Fazli Khuda; Ghadeer M Albadrani; Jawaher A Abdulhakim; Ahmed E Altyar; Mohamed M Abdel-Daim; Syed Muhammad Ashhad Halimi; Atif Ali Khan Khalil
Journal:  Medicina (Kaunas)       Date:  2022-08-10       Impact factor: 2.948

7.  Obesity and metabolic dysfunction drive sex-associated differential disease profiles in hACE2-mice challenged with SARS-CoV-2.

Authors:  Katherine S Lee; Brynnan P Russ; Ting Y Wong; Alexander M Horspool; Michael T Winters; Mariette Barbier; Justin R Bevere; Ivan Martinez; F Heath Damron; Holly A Cyphert
Journal:  iScience       Date:  2022-09-02

8.  Risk Factors Associated with Mortality in COVID-19 Hospitalized Patients: Data from the Middle East.

Authors:  Reema A Karasneh; Basheer Y Khassawneh; Sayer Al-Azzam; Abdel-Hameed Al-Mistarehi; William J Lattyak; Motasem Aldiab; Suad Kabbaha; Syed Shahzad Hasan; Barbara R Conway; Mamoon A Aldeyab
Journal:  Int J Clin Pract       Date:  2022-08-16       Impact factor: 3.149

9.  Knowledge4COVID-19: A semantic-based approach for constructing a COVID-19 related knowledge graph from various sources and analysing treatments' toxicities.

Authors:  Ahmad Sakor; Samaneh Jozashoori; Emetis Niazmand; Ariam Rivas; Kostantinos Bougiatiotis; Fotis Aisopos; Enrique Iglesias; Philipp D Rohde; Trupti Padiya; Anastasia Krithara; Georgios Paliouras; Maria-Esther Vidal
Journal:  Web Semant       Date:  2022-10-13       Impact factor: 2.770

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.